Potential diagnostic biomarkers MINK1, PLEKHM3, BZW1, and RCF2 had mRNA expression that differed significantly between GBM and the other glioma subtypes (p-values < 0.001; Figure S5). Here, PLEKHM3 is linked to central nervous system cancer.